Journal of Clinical Endocrinology & Metabolism, Vol 81, 2934-2941, Copyright © 1996 by Endocrine Society

ARTICLES

Plasma corticotropin and cortisol responses to ovine corticotropin- releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease

G Dickstein, CR DeBold, D Gaitan, GS DeCherney, RV Jackson, WR Sheldon Jr, WE Nicholson and DN Orth
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.

The CRH test may sometimes be useful in the differential diagnosis of Cushing's syndrome, because most patients with pituitary ACTH-dependent Cushing's syndrome (Cushing's disease) respond to CRH, but those with other causes of Cushing's syndrome usually do not. However, about 10% of Cushing's disease patients fail to respond to CRH. We wondered if we could eliminate these false negative results either by exploiting the potential additive or synergistic effects of another ACTH secretagogue or by reducing glucocorticoid inhibition of CRH's ACTH-releasing effect. We compared the effect on plasma ACTH and cortisol in 51 patients with Cushing's disease of administering ovine CRH (1 microgram/kg BW, i.v.) alone, arginine vasopressin (AVP; 10 U, i.m.) alone, the combination of CRH and AVP, and CRH after pretreatment with metyrapone (1 g, orally, every 4 h for three doses; CRH + MET). The rates of nonresponse (ACTH increment, < 35%; cortisol increment, < 20%) to AVP and CRH alone were 26% and 8%, respectively; all patients responded to CRH + AVP. The lack of response was not due to improper administration or rapid metabolism of the agonist, because plasma CRH and AVP concentrations were similar in responders and nonresponders. A synergistic ACTH response to CRH + AVP occurred in 65% of the patients. MET pretreatment increased basal plasma ACTH levels in most patients and induced the greatest mean peak ACTH response to CRH, but 8% of the patients did not respond to CRH + MET with an ACTH increment of 35% or more. Because all of the Cushing's disease patients tested in this study responded to the combination of CRH + AVP, whereas 8% failed to respond to CRH alone, we conclude that CRH + AVP administration may provide a more reliable test for the differential diagnosis of ACTH- dependent Cushing's syndrome than administration of CRH alone. Whether this improved sensitivity is accompanied by unaltered specificity for Cushing's disease must be tested in patients with chronic ectopic ACTH syndrome.

This article has been cited by other articles:

				T. Tateno, H. Izumiyama, M. Doi, T. Yoshimoto, M. Shichiri, N. Inoshita, K. Oyama, S. Yamada, and Y. Hirata Differential gene expression in ACTH -secreting and non-functioning pituitary tumors Eur. J. Endocrinol., December 1, 2007; 157(6): 717 - 724. [Abstract] [Full Text] [PDF]

				C. S.-L. Gal, D. Raufaste, S. Derick, J. Blankenstein, J. Allen, B. Pouzet, M. Pascal, J. Wagnon, and M. A. Ventura Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R938 - R949. [Abstract] [Full Text] [PDF]

				R M Testa, N Albiger, G Occhi, F Sanguin, M Scanarini, S Berlucchi, M P Gardiman, C Carollo, F Mantero, and C Scaroni The usefulness of combined biochemical tests in the diagnosis of Cushing's disease with negative pituitary magnetic resonance imaging Eur. J. Endocrinol., February 1, 2007; 156(2): 241 - 248. [Abstract] [Full Text] [PDF]

				J. Newell-Price, D. G. Morris, W. M. Drake, M. Korbonits, J. P. Monson, G. M. Besser, and A. B. Grossman Optimal Response Criteria for the Human CRH Test in the Differential Diagnosis of ACTH-Dependent Cushing's Syndrome J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1640 - 1645. [Abstract] [Full Text] [PDF]

				S. Tsagarakis, C. Tsigos, V. Vasiliou, P. Tsiotra, J. Kaskarelis, C. Sotiropoulou, S. A. Raptis, and N. Thalassinos The Desmopressin and Combined CRH-Desmopressin Tests in the Differential Diagnosis of ACTH-Dependent Cushing's Syndrome: Constraints Imposed by the Expression of V2 Vasopressin Receptors in Tumors with Ectopic ACTH Secretion J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1646 - 1653. [Abstract] [Full Text] [PDF]

				C. S.-L. Gal, J. Wagnon, J. Simiand, G. Griebel, C. Lacour, G. Guillon, C. Barberis, G. Brossard, P. Soubrie, D. Nisato, et al. Characterization of (2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1122 - 1130. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, M. G. Giannulis, J. D. C. Newell-Price, J. E. Dacie, C. Thakkar, F. Afshar, J. P. Monson, A. B. Grossman, G. M. Besser, and P. J. Trainer A Critical Analysis of the Value of Simultaneous Inferior Petrosal Sinus Sampling in Cushing's Disease and the Occult Ectopic Adrenocorticotropin Syndrome J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 487 - 492. [Abstract] [Full Text]

				J. Newell-Price, P. Trainer, M. Besser, and A. Grossman The Diagnosis and Differential Diagnosis of Cushing's Syndrome and Pseudo-Cushing's States Endocr. Rev., October 1, 1998; 19(5): 647 - 672. [Abstract] [Full Text]

				G. Arnaldi, J.-M. Gasc, Y. de Keyzer, M.-L. Raffin-Sanson, V. Perraudin, J.-M. Kuhn, M.-C. Raux-Demay, J.-P. Luton, E. Clauser, and X. Bertagna Variable Expression of the V1 Vasopressin Receptor Modulates the Phenotypic Response of Steroid-Secreting Adrenocortical Tumors J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2029 - 2035. [Abstract] [Full Text]